Art. -Nr.: HY-10578

PD 169316

28 Cited Publications

Kundenbewertung

Based on 28 publication(s) in Google Scholar

PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC₅₀ of 89 nM. PD169316 selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. PD169316 shows antiviral activity against Enterovirus71. PD169316 shows antiviral activity against Enterovirus71.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.07%
CAS. Nr.: 152121-53-4
Formel: C₂₀H₁₃FN₄O₂
Molecular Weight:360.34

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

PD 169316 Chemical Structure

CAS. Nr.: 152121-53-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (28)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 89 nM (p38 MAPK)^[5]

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
RBL-1	IC₅₀	8 μM Compound: 22	Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells	10.1016/0960-894X(95)00189-Z

In Vitro

PD169316 (10 μM) inhibits TGFβ and Activin A, but not BMP4 signaling in CaOV3 cells. PD169316 (0.2-20 μM) inhibits TGFβ-induced Smad2 nuclear translocation, Smad7 mRNA induction, and reporter gene activity in CaOV3 cells^[1]. PD169316 (10 μM) shows a significantly increased rate of proliferation in Nestin knockdown cells, and can rescue the effect of Nestin knockdown on cell viability in the absence of EGF^[2]. PD169316 significantly inhibits p38 MAP kinase activity with no significant change in ERK activity in PC12 cells. PD169316 (10 μM) blocks apoptosis induced by trophic factor withdrawal in differentiated PC12 cells^[3].PD169316 (10 μM, 30 min) selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. Increased phospho p-38 levels in the presence of PD169316 are most likely due to blockade of negative feedback loop of dephosphorylation of p38 MAPK by MAPK phosphatases^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Ishikawa PRB or PRA cells.
Concentration:

10 μM.
Incubation Time:

30 min.
Result:

Did not inhibit MEKK1-induced p38 phosphorylation.

In Vivo

PD169316 (1 mg/kg, intramuscular injection every day for 14 consecutive days) shows antiviral activity in a suckling mouse model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

EV71-challenged suckling mouse model (7-day-old Kunming mice)^[5].
Dosage:

1 mg/kg.
Administration:

Intramuscular injection every day for 14 consecutive days.
Result:

Showed antiviral activity.

Chemical Information

CAS. Nr. 152121-53-4
Appearance Solid
Molecular Weight 360.34
Formel C₂₀H₁₃FN₄O₂
Color Light yellow to yellow
SMILES

FC(C=C1)=CC=C1C2=C(C3=CC=NC=C3)NC(C4=CC=C([N+]([O-])=O)C=C4)=N2
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (28)

All WB

Sort by:

Journal Impact Factor

Bioact Mater

Nanoporous titanium implant surface promotes osteogenesis by suppressing osteoclastogenesis via integrin β1/FAKpY397/MAPK pathway. [Abstract]

2021 Jul 1:8:109-123. PMID: 34541390
Metabolism

Chemical discovery of a novel MD2/ADAM17 dual-target inhibitor as a potential therapeutic candidate for saturated fatty acid-induced myocardial inflammatory injury. [Abstract]

2025 Aug:169:156298. PMID: 40381836
Interdiscip Med

2026 May 18.
Adv Sci (Weinh)

Neutrophil Mobilization Triggers Microglial Functional Change to Exacerbate Cerebral Ischemia-Reperfusion Injury. [Abstract]

2025 Sep;12(36):e03722. PMID: 40557450
Adv Sci (Weinh)

Regulation of Neuroinflammation by Microglial DUBA-IRAK1-IKKβ Signaling Loop. [Abstract]

2025 Aug 4:e03972. PMID: 40755418
Cell Rep Med

HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]

2026 Apr 21;7(4):102691. PMID: 41861828
Cell Death Differ

EGFR orchestrates neutrophil activation and NETosis via CEBPβ-dependent PGLYRP1 induction. [Abstract]

2026 Jan 15. PMID: 41540251
Cancer Lett

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer. [Abstract]

2025 Aug 29:633:218010. PMID: 40886822
ACS Appl Mater Interfaces

The Translation from In Vitro Bioactive Ion Concentration Screening to In Vivo Application for Preventing Peri-implantitis. [Abstract]

2021 Feb 3;13(4):5782-5794. PMID: 33464812
Brain Behav Immun

TLR9 in satellite glial cells promotes paclitaxel-induced neuropathic pain by reducing Kir4.1 transcription through histone methylation activation. [Abstract]

2025 Mar 31:S0889-1591(25)00122-9. PMID: 40174869
Br J Pharmacol

Blockade of the forward Na+ /Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+ -mediated cell death. [Abstract]

2019 Aug;176(15):2691-2707. PMID: 31034096
Genes Dev

Dynamic turnover of paused Pol II complexes at human promoters. [Abstract]

2018 Sep 1;32(17-18):1215-1225. PMID: 30150253
Hum Reprod

Increased AIF-1-mediated p38 MAPK phosphorylation in the mid-secretory endometrium impairs endometrial receptivity in women with recurrent implantation failure. [Abstract]

2025 Sep 26:deaf174. PMID: 41003697
Antioxid Redox Signal

TXNIP exacerbates the senescence and ageing-related dysfunction of β-cells by inducing cell cycle arrest through p38-p16/p21-CDK-Rb pathway. [Abstract]

2023 Mar;38(7-9):480-495. PMID: 36070438
Ecotoxicol Environ Saf

SKI-606, a Src inhibitor, ameliorates benzene-induced hematotoxicity via blocking ROS/Src kinase-mediated p38 and Akt signaling pathways. [Abstract]

2024 Nov 1:286:117223. PMID: 39447291
Ecotoxicol Environ Saf

TNF-α derived from arsenite-induced microglia activation mediated neuronal necroptosis. [Abstract]

2022 May 1;236:113468. PMID: 35378400
Int J Mol Sci

Transcriptional Repression of CCL2 by KCa3.1 K+ Channel Activation and LRRC8A Anion Channel Inhibition in THP-1-Differentiated M2 Macrophages. [Abstract]

2025 Aug 6;26(15):7624. PMID: 40806751
Chem Biol Interact

Lanostane triterpenoids from Ganoderma calidophilum exhibit potent anti-tumor activity by inhibiting PTP1B. [Abstract]

2024 Nov 1:403:111253. PMID: 39341486
Mol Cell Biochem

MAPK signaling mediated intestinal inflammation induced by endoplasmic reticulum stress and NOD2. [Abstract]

2025 Jun;480(6):3709-3717. PMID: 39806198
Oncol Rep

Cisplatin-induced autophagy protects breast cancer cells from apoptosis by regulating yes-associated protein. [Abstract]

2017 Dec;38(6):3668-3676. PMID: 29039616

PD 169316 purchased from MedChemExpress. Usage Cited in: Oncol Rep. 2017 Dec;38(6):3668-3676. [Abstract]

Western blot analysis evaluated p-p38, p38, LC3 and quantification of LC3-II in untreated (control), treated with the p38 inhibitor PD169316, cisplatin, and both these agents in MDA-MB-231 cells.
J Virol

Critical Role of Viral Protein Hexon in Hypervirulent Fowl Adenovirus Serotype-4-Induced Autophagy by Interaction with BAG3 and Promotion of Viral Replication in LMH Cells. [Abstract]

2023 Jun 29;97(6):e0028423. PMID: 37255472
Int J Med Sci

NLS-RARα Inhibits the Effects of All-trans Retinoic Acid on NB4 Cells by Interacting with P38α MAPK. [Abstract]

2016 Jul 18;13(8):611-9. PMID: 27499693

PD 169316 purchased from MedChemExpress. Usage Cited in: Int J Med Sci. 2016 Jul 18;13(8):611-9. [Abstract]

PD169316 (10 μM) inhibits the effects of all-trans retinoic acid(ATRA) on nuclear localization signal retinoic acid receptor alpha (NLS-RARα)-overexpressed NB4 cells incluing an increase of the expressions of p-p38α, C/EBPβ and CD11b.
Mol Cell Biol

Kinase Inhibitor-Induced Cell-Type Specific Vacuole Formation in the Absence of Canonical ATG5-Dependent Autophagy Initiation Pathway. [Abstract]

2025;45(3):99-115. PMID: 39895059
Virology

PD169316, a specific p38 inhibitor, shows antiviral activity against Enterovirus71. [Abstract]

2017 Aug:508:150-158. PMID: 28545002
Oncol Lett

Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. [Abstract]

2018 Jan;15(1):235-242. PMID: 29387217

PD 169316 purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Jan;15(1):235-242. [Abstract]

Cells are treated with 15 and 20 μM Lapatinib for 24 h, the expression of p AKT, AKT, p p38 MAPK, p38 MAPK, p JNK, and JNK are measured by western blotting. Quantification analysis of western blotting, β actin is served as a control. D: 1 DMSO; 2 PD169316; 3 15 μM Lapatinib; 4 PD169316+15 μM Lapatinib).
Oncol Lett

Epigallocatechin-3-gallate induces apoptosis in acute promyelocytic leukemia cells via a SHP-1-p38α MAPK-Bax cascade. [Abstract]

2017 Nov;14(5):6314-6320. PMID: 29113283
bioRxiv

Shigella OspF blocks rapid p38-dependent priming of the NAIP-NLRC4 inflammasome. [Abstract]

2025 Feb 2:2025.02.01.636075. PMID: 39975412
Chinese Journal of Cell Biology

2016, 38(7): 770–776

PD 169316 purchased from MedChemExpress. Usage Cited in: Chinese Journal of Cell Biology. 2016, 38(7): 770–776

The protein levels of Bax and Bcl-2 detected by Western blot. PD169316 decreases EGCG-mediated increases in Bax protein expression.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 12.5 mg/mL (34.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7752 mL

13.8758 mL

27.7516 mL

5 mM

0.5550 mL

2.7752 mL

5.5503 mL

10 mM

0.2775 mL

1.3876 mL

2.7752 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 1.25 mg/mL (3.47 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1.25 mg/mL (3.47 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (3.47 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (13.88 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (582 KB)
- English - EN (582 KB)
- Français - FR (582 KB)
- Deutsch - DE (582 KB)
- Norwegian - NO (582 KB)
- Español - ES (582 KB)
- Swedish - SV (582 KB)
- Italian - IT (582 KB)
- Korean - KR (582 KB)
- Portuguese - PT (582 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Fu Y, et al. The p38 MAPK inhibitor, PD169316, inhibits transforming growth factor beta-induced Smad signaling in human ovarian cancer cells. Biochem Biophys Res Commun. 2003 Oct 17;310(2):391-7. [Content Brief]

[2]. Hu W, et al. Suppression of Nestin reveals a critical role for p38-EGFR pathway in neural progenitor cell proliferation. Oncotarget. 2016 Dec 27;7(52):87052-87063. [Content Brief]

[3]. Kummer JL, et al. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem. 1997 Aug 15;272(33):20490-4. [Content Brief]

[4]. Khan JA, et al. p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol. 2011 Oct;25(10):1710-24. [Content Brief]

[5]. Zhang Z, et al. PD169316, a specific p38 inhibitor, shows antiviral activity against Enterovirus71. Virology. 2017 Aug;508:150-158. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7752 mL	13.8758 mL	27.7516 mL	69.3789 mL
	5 mM	0.5550 mL	2.7752 mL	5.5503 mL	13.8758 mL
	10 mM	0.2775 mL	1.3876 mL	2.7752 mL	6.9379 mL
	15 mM	0.1850 mL	0.9251 mL	1.8501 mL	4.6253 mL
	20 mM	0.1388 mL	0.6938 mL	1.3876 mL	3.4689 mL
	25 mM	0.1110 mL	0.5550 mL	1.1101 mL	2.7752 mL
	30 mM	0.0925 mL	0.4625 mL	0.9251 mL	2.3126 mL

Keywords

PD 169316

28 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PD 169316

Kinase Inhibitor Library

MAPK Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lactylation Compound Library

Immunology/Inflammation Compound Library

Anti-Aging Compound Library Mini

Anti-Infection Compound Library

Publications Citing Use of MedChemExpress (MCE) PD 169316

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (28)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

PD 169316 Related Classifications

HY-10578 Related Classifications